TAP Study C02-039
A Phase 2, Open-Label Multi-Center Study to Evaluate the Pharmacodynamics of Intravenous Lansoprazole to that of Oral Lansoprazole in Subjects with Erosive Esophagitis.
The content of this web site is supplied for informational purposes only and should not be construed as medical advice. Patients should consult their health care professional for advice on their specific situation.
Nothing in TAP’s posting of information is intended to be viewed as any claim for a particular marketed or unmarketed product. Some clinical studies may include information not contained in the approved package insert. Please refer to the full prescribing information for additional information.
TAP Pharmaceutical Products Inc. (“TAP”) will use reasonable efforts to include accurate and up-to-date information consistent with TAP policies and procedures, on the ClinicalStudyResults.org web site. However because the status of studies often changes, TAP makes no warranties or representations of any kind as to the current status or completeness of the information contained therein.
Persons accessing and using information posted by TAP on the ClinicalStudyResults.org web site do so at their own risk. TAP hereby disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. TAP shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use or inability to use information posted by TAP on the ClinicalStudyResults.org web site, or any errors or omission in the content thereof.
To view this study on clinicaltrials.gov: http://www.clinicaltrials.gov/ct/show/NCT00175045
For FDA Safety Alerts and Recalls refer to the following link: www.fda.gov/MEDWATCH/safety.htm
|
